



1623 PATENT
Attorney Docket No. 214654
Date: January 23, 2003

In re Application of: Ts'o et al.
Application No. 09/998,497
Filed: November 30, 2001
For: CONJUGATES OF GLYCOSYLATED/GALACTOSYLATED PEPTIDE, BIFUNCTIONAL LINKER, AND NUCLEOTIDIC MONOMERS/POLYMERS AND RELATED COMPOSITIONS AND METHODS OF USE.

TECH CENTER 1600/2800
FEB 07 2003
RECEIVED

COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Sir:

Transmitted herewith is a Response to Restriction Requirement in the subject application.

- Applicants claim small entity status of this application under 37 CFR 1.27.
- Petition for Extension of Time
 - Applicants petition for a one-month extension of time under 37 CFR 1.136, the fee for which is \$110.00 (enclosed).
 - Applicants believe that no petition for an extension of time is necessary. However, to the extent that such petition is deemed necessary, Applicants hereby petition for a sufficient extension of time to render the present submission timely. Please charge Deposit Account No. 12-1216 for the appropriate petition fee.
- No additional claim fee is required.
- Other:


The claim fee has been calculated as shown below:

| | | CLAIMS REMAINING AFTER AMENDMENT | HIGHEST NUMBER PREVIOUSLY PAID FOR | EXTRA CLAIMS PRESENT | SMALL ENTITY RATE | OTHER THAN A SMALL ENTITY RATE |
|---|--|---|---|----------------------------|----------------------|--------------------------------------|
| TOTAL | | MINUS | | = | x 9= | \$ |
| INDEPENDENT | | MINUS | | = | x 42= | \$ |
| <input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE CLAIM | | | | + 140= | \$ | + 280= |
| | | | | TOTAL | \$ | TOTAL |

- Please charge my Deposit Account No. 12-1216 in the amount of \$ A duplicate copy of this sheet is attached.
- A check in the amount of \$ is attached.
- The Commissioner is hereby authorized to charge any deficiencies in the following fees associated with this communication or credit any overpayment to Deposit Account No. 12-1216. A duplicate copy of this sheet is attached.
 - Any filing fees under 37 CFR 1.16 for the presentation of extra claims.
 - Any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

LEYDIG VOIT & MAYER, LTD.

By 
Carol Larcher, Reg. No. 35,243

Leydig, Voit & Mayer, Ltd.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

RECEIVED
FEB 07 2003
TECH CENTER 1600/2900



THE PATENT AND TRADEMARK OFFICE IS RESPECTFULLY REQUESTED TO PLACE ITS STAMP ON THIS POSTAL CARD AND PLACE IT IN THE OUTGOING MAIL TO SHOW THE FOLLOWING PAPERS HAVE BEEN RECEIVED.

Attorney Docket: 214654

In Re Application of: Ts'o et al.

U.S. Patent Application: 09/998,497

Filed: November 30, 2001

For: "CONJUGATES OF GLYCOSYLATED/GALACTOSYLATED PEPTIDE,
BIFUNCTIONAL LINKER, AND NUCLEOTIDIC MONOMERS/POLYMERS AND
RELATED COMPOSITIONS AND METHODS OF USE."

Enclosed: Transmittal Sheet (1 page in duplicate); Response to Restriction
Requirement with Certificate of Mailing (4 pages); and postcard.

Mailed: January 23, 2003

CL/kng



Attorney Docket No. 2146544-001

#7
2-20-03
PATENT
RECEIVED
FEB 07 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Ts'o et al.

Application No. 09/998,497

Filed: November 30, 2001

Art Unit: 1623

Examiner: H.V. Owens, Jr.

For: CONJUGATES OF GLYCOSYLATED/
GALACTOSYLATED PEPTIDE,
BIFUNCTIONAL LINKER, AND
NUCLEOTIDIC
MONOMERS/POLYMERS AND
RELATED COMPOSITIONS AND
METHODS OF USE

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated December 23, 2002, please consider the following remarks.

REMARKS

The Requirement for Restriction

The Office has set forth the following requirement for restriction:

- (i) claims 1-54, as directed to a peptide-nucleotide conjugate composition, classified in class 530, subclass 322;
- (ii) claims 55-58 as directed to a method of inhibiting cellular proliferation using a peptide-nucleotide conjugate, classified in class 514, subclass 8+; and
- (iii) claims 59-62 as directed to a method of inhibiting a virus using a peptide-nucleotide conjugate, classified in class 514, subclass 8+.